383 related articles for article (PubMed ID: 21636861)
1. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.
Scully M; McDonald V; Cavenagh J; Hunt BJ; Longair I; Cohen H; Machin SJ
Blood; 2011 Aug; 118(7):1746-53. PubMed ID: 21636861
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.
Westwood JP; Webster H; McGuckin S; McDonald V; Machin SJ; Scully M
J Thromb Haemost; 2013 Mar; 11(3):481-90. PubMed ID: 23279219
[TBL] [Abstract][Full Text] [Related]
3. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
4. Rituximab in the treatment of TTP.
Scully M
Hematology; 2012 Apr; 17 Suppl 1():S22-4. PubMed ID: 22507771
[TBL] [Abstract][Full Text] [Related]
5. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
[TBL] [Abstract][Full Text] [Related]
6. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays.
McDonald V; Liesner R; Grainger J; Gattens M; Machin SJ; Scully M
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):245-50. PubMed ID: 20083997
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.
Narayanan P; Jayaraman A; Rustagi RS; Mahadevan S; Parameswaran S
Int J Hematol; 2012 Jul; 96(1):122-4. PubMed ID: 22552883
[TBL] [Abstract][Full Text] [Related]
8. Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab.
Goyal J; Adamski J; Lima JL; Marques MB
J Clin Apher; 2013 Dec; 28(6):390-4. PubMed ID: 23857472
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.
Froissart A; Buffet M; Veyradier A; Poullin P; Provôt F; Malot S; Schwarzinger M; Galicier L; Vanhille P; Vernant JP; Bordessoule D; Guidet B; Azoulay E; Mariotte E; Rondeau E; Mira JP; Wynckel A; Clabault K; Choukroun G; Presne C; Pourrat J; Hamidou M; Coppo P;
Crit Care Med; 2012 Jan; 40(1):104-11. PubMed ID: 21926591
[TBL] [Abstract][Full Text] [Related]
10. Short- and long-term effects of rituximab for the treatment of thrombotic thrombocytopenic purpura: four case reports.
Iioka F; Shimomura D; Ishii T; Maesako Y; Ohgoe K; Nakamura F; Matsuo S; Ohno H
Int J Hematol; 2012 Oct; 96(4):506-12. PubMed ID: 22878941
[TBL] [Abstract][Full Text] [Related]
11. Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature.
Montoya RC; Poiesz BJ
Blood Coagul Fibrinolysis; 2012 Jun; 23(4):338-41. PubMed ID: 22498981
[TBL] [Abstract][Full Text] [Related]
12. Rituximab as preventive therapy of a clinical relapse in TTP with ADAMTS13 inhibitor.
Schleinitz N; Ebbo M; Mazodier K; Poullin P; Bernit E; Veit V; Veyradier A; Fakhouri F; Kaplanski G; Harle JR
Am J Hematol; 2007 May; 82(5):417-8. PubMed ID: 17266057
[No Abstract] [Full Text] [Related]
13. Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.
Ferrari S; Palavra K; Gruber B; Kremer Hovinga JA; Knöbl P; Caron C; Cromwell C; Aledort L; Plaimauer B; Turecek PL; Rottensteiner H; Scheiflinger F
Haematologica; 2014 Apr; 99(4):779-87. PubMed ID: 24241492
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature.
Rüfer A; Brodmann D; Gregor M; Kremer Hovinga JA; Lämmle B; Wuillemin WA
Swiss Med Wkly; 2007 Sep; 137(37-38):518-24. PubMed ID: 17990141
[TBL] [Abstract][Full Text] [Related]
15. Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab.
Hagel S; Jantsch J; Budde U; Kalden JR; Eckardt KU; Veelken R
Thromb Haemost; 2008 Jul; 100(1):151-3. PubMed ID: 18612551
[No Abstract] [Full Text] [Related]
16. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with rituximab for acute refractory thrombotic thrombocytopenic purpura related to acquired ADAMTS13 deficiency: a pediatric report and literature review.
Harambat J; Lamireau D; Delmas Y; Ryman A; Llanas B; Brissaud O
Pediatr Crit Care Med; 2011 Mar; 12(2):e90-3. PubMed ID: 20625343
[TBL] [Abstract][Full Text] [Related]
18. [Successful treatment of idiopathic acquired refractory thrombotic thrombocytopenic purpura with an association of rituximab-vindesine. Report of one case].
Ojeda-Uribe M; Brunot A; Issler M
Rev Med Chil; 2005 Nov; 133(11):1349-54. PubMed ID: 16446859
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
Chemnitz JM; Uener J; Hallek M; Scheid C
Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
